ELISA/assay

Rat Kelch-like ECH-associated protein 1 (KEAP1) ELISA Kit

MBS7218529

48-Strip-Wells

470 USD

ELISA Kit

Rat Kelch-like ECH-associated protein 1 (KEAP1) ELISA Kit

Kelch-like ECH-associated protein 1 (KEAP1)

kelch-like ECH-associated protein 1; Kelch-like ECH-associated protein 1; kelch-like ECH-associated protein 1; kelch-like protein 19; cytosolic inhibitor of Nrf2; kelch-like family member 19; kelch-like ECH-associated protein 1; Cytosolic inhibitor of Nrf2; INrf2; Kelch-like protein 19

KEAP1

KEAP1; KEAP1; INrf2; KLHL19; INRF2; KIAA0132; KLHL19; INrf2

KEAP1_HUMAN

Rat

This assay has high sensitivity and excellent specificity for detection of KEAP1. No significant cross-reactivity or interference between KEAP1 and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between KEAP1 and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 0.1 ng/mL.

Intended Uses: This KEAP1 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Rat KEAP1. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Epigenetics and Nuclear Signaling

Principle of the assay: KEAP1 ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-KEAP1 antibody and an KEAP1-HRP conjugate. The assay sample and buffer are incubated together with KEAP1-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the KEAP1 concentration since KEAP1 from samples and KEAP1-HRP conjugate compete for the anti-KEAP1 antibody binding site. Since the number of sites is limited, as more sites are occupied by KEAP1 from the sample, fewer sites are left to bind KEAP1-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The KEAP1 concentration in each sample is interpolated from this standard curve.

22027642

NP_036421.2

NM_012289.3

69,666 Da

Adaptive Immune System Pathway (366160); Antigen Processing: Ubiquitination Proteasome Degradation Pathway (366162); Class I MHC Mediated Antigen Processing Presentation Pathway (366161); Immune System Pathway (106386); Keap1-Nrf2 Pathway (198777); Ubiquitin Mediated Proteolysis Pathway (83056); Ubiquitin Mediated Proteolysis Pathway (466)

This gene encodes a protein containing KELCH-1 like domains, as well as a BTB/POZ domain. Kelch-like ECH-associated protein 1 interacts with NF-E2-related factor 2 in a redox-sensitive manner and the dissociation of the proteins in the cytoplasm is followed by transportation of NF-E2-related factor 2 to the nucleus. This interaction results in the expression of the catalytic subunit of gamma-glutamylcysteine synthetase. Two alternatively spliced transcript variants encoding the same isoform have been found for this gene. [provided by RefSeq, Jul 2008]

KEAP1: a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1. Has tumor suppressor activity. Retains NRF2, BPTF and PGAM5 in the cytosol. Targets NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and of antioxidant response element-mediated detoxifying enzyme gene expression. Somatic mutations of KEAP1 or NRF2 commonly occur in solid cancers, irrespective of histological type, resulting in the constitutive transcription of cytoprotective genes. Genetic disruption of the KEAP1/CUL3 E3 ubiquitin ligase complex leads to the activation of the NF-kappaB pathway in lung cancer. Alternative activation of the cytoprotective NRF2 pathway exist in the absence of mutations in KEAP1 and HRF2: WTX, PALB2, SQSTM1, and DPP3 can competitively bind KEAP1. These proteins and others that bind KEAP1 contain an ¿ETGE¿ amino acid motif, which matches the KEAP1 interaction motif found in NRF2. Binding of these ¿ETGE¿-containing proteins can displace NRF2, freeing it to translocate to the nucleus and implement its cytoprotective transcriptional pathway. The DPP3 gene is frequently overexpressed in squamous cell lung carcinomas with high wt NRF2 activity. Its expression level significantly correlates with the response rate and progression-free survival of platinum-based first-line chemotherapy. May be a useful biomarker for predicting the chemosensitivity of patients with advanced-stage NSCLC. Broadly expressed, with highest levels in skeletal muscle. Ubiquitination and subsequent degradation of PGAM5 is inhibited by oxidative stress and sulforaphane. Protein type: Transcription regulation; Ubiquitin conjugating system; Motility/polarity/chemotaxis; Endoplasmic reticulum. Chromosomal Location of Human Ortholog: 19p13.2. Cellular Component: nucleoplasm; endoplasmic reticulum; cytoplasm; microtubule organizing center; midbody; cytosol. Molecular Function: protein binding; transcription factor binding. Biological Process: transcription, DNA-dependent; in utero embryonic development; negative regulation of transcription factor activity; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; proteasomal ubiquitin-independent protein catabolic process; protein ubiquitination; regulation of epidermal cell differentiation

48-Strip-Wells

470 USD

96-Strip-Wells

675